New Study Shows Promise in Restoring Brain's Defenses Against Alzheimer's
Researchers have uncovered a surprising immune-system switch in the brain that could open a new avenue in the fight the disease.
A recent study has revealed a potential method for restoring the brain's immune response and alleviating abnormal nerve cell activity associated with Alzheimer's disease. The research, led by Professor Minah Suh from Sungkyunkwan University and in collaboration with Professor Ho-Keun Kwon's team at Yonsei University College of Medicine, investigated the brain's immune cells, known as microglia.
These cells typically serve as the brain's first line of defense, detecting and responding to damage while preserving a healthy surrounding environment. However, in Alzheimer's disease, this response is impaired, and nerve cells exhibit excessive activity. The study, published in Science Advances, linked this disruption to alterations in two immune-regulating proteins, PD-1 and PD-L1, in microglia and astrocytes.
To explore the impact of these changes, the researchers administered an antibody that blocks PD-L1 directly into the brains of Alzheimer's disease model mice. Advanced microscopy techniques revealed that the microglia regained their ability to respond appropriately to damaged areas, and excessive neuron activity was reduced. Dr. John Showalter, chief operating officer of Linus Health, highlighted that the research contributes to growing evidence of the immune system's role in Alzheimer's disease and dementia.
He also noted that individuals who receive the shingles vaccine are less likely to develop dementia, suggesting a potential link between the immune system and cognitive decline. The study indicates that targeting immune cells, specifically microglia, may be a promising avenue for addressing the disease. The researchers propose that disrupted immune signaling could be responsible for abnormal microglial behavior and excessive neuronal activity, contributing to an unhealthy brain environment.
While the study does not confirm that blocking PD-L1 can treat or cure Alzheimer's disease in humans, it does provide evidence for a potential therapeutic approach. However, delivering antibodies directly to the brain and spinal cord fluid presents significant challenges, and further research is needed to determine if the same effects could occur in humans.
Written by urgent.news from Newsweek's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
